Moberg Pharma ABFRA:MB8 +0.50%60 PS Ratio is 27.66 as of Jul. 04, 2026, which is 650% above its 10-year median of 3.69. GuruFocus rates FRA:MB8 with a GF Score™ of 60/100 and a GF Value™ of €1.06. The stock has 1 warning sign investors should review. Among 950 Drug Manufacturers companies, Moberg Pharma AB ranks worse than 95.58% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Moberg Pharma AB's share price is €0.802.
Moberg Pharma AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €0.03. Hence, Moberg Pharma AB's PS Ratio for today is 27.66.
Good Sign:
Moberg Pharma AB stock PS Ratio (=31.09) is close to 1-year low of 30.27.
The historical rank and industry rank for Moberg Pharma AB's PS Ratio or its related term are showing as below:
FRA:MB8'
s PS Ratio Range Over the Past 10 Years
Min: 0.82 Med: 3.69 Max: 2196.47
Current: 31.09
During the past 13 years, Moberg Pharma AB's highest PS Ratio was 2196.47. The lowest was 0.82. And the median was 3.69.
FRA:MB8's PS Ratio is ranked worse than 95.58% of 950
companies
in the Drug Manufacturers industry
Industry Median: 2.315
vs FRA:MB8: 31.09
During the past 13 years, Moberg Pharma AB's highest 3-Year average Revenue per Share Growth Rate was 168.90% per year. The lowest was -95.00% per year. And the median was 19.00% per year.
Back to Basics: PS Ratio
Moberg Pharma AB (FRA:MB8) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Moberg Pharma AB PS Ratio Related Terms
Moberg Pharma AB PS Ratio Historical Data
* Premium members only.
The historical data trend for Moberg Pharma AB's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Moberg Pharma AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moberg Pharma AB PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Moberg Pharma AB's PS Ratio distribution charts can be found below:
* The bar in red indicates where Moberg Pharma AB's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Moberg Pharma AB's Share Price of today is €0.802. Moberg Pharma AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.03.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Moberg Pharma AB (FRA:MB8) has a PS Ratio of 27.66 as of Jul. 04, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Moberg Pharma AB and its competitors. This is 650% above median its historical median of 3.69. Over the past decade, Moberg Pharma AB's PS Ratio has ranged from 0.82 to 2,196.47. According to the industry distribution chart, Moberg Pharma AB ranks #908 out of 950 companies in the Drug Manufacturers industry, placing it in the top 95.6%.
Is Moberg Pharma AB's PS Ratio too high?
Moberg Pharma AB's current PS Ratio of 27.66 is 650% above median its 10-year median of 3.69. Over the past 10 years, this metric has ranged from a low of 0.82 to a high of 2,196.47. The Drug Manufacturers industry median PS Ratio is 2.32. Moberg Pharma AB's value of 27.66 is 1094.8% above this industry median. Based on the distribution chart, Moberg Pharma AB ranks #908 out of 950 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Moberg Pharma AB has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Moberg Pharma AB's PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Moberg Pharma AB ranks #908 out of 950 companies for PS Ratio. This places Moberg Pharma AB in the lower half of its industry. The industry median PS Ratio is 2.32. Moberg Pharma AB's value of 27.66 is 1094.8% above this benchmark. Historically, Moberg Pharma AB's own PS Ratio has ranged from 0.82 to 2,196.47 over the past decade. While the company's 10-year median is 3.69 vs. the industry median of 2.32, Moberg Pharma AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.32, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Moberg Pharma AB's current PS Ratio of 27.66 is 1094.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Moberg Pharma AB and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Moberg Pharma AB's current PS Ratio is 27.66, which is 650% above median its own 10-year median of 3.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moberg Pharma AB stock overvalued right now?
Moberg Pharma AB (FRA:MB8) has a current PS Ratio of 27.66. The stock's GF Value™ is €1.06, compared to a current price of €0.80 — trading 24.3% below its estimated fair value. The current PS Ratio is 27.66, which is 650% above median its 10-year median of 3.69 and 1094.8% above the Drug Manufacturers industry median of 2.32. Moberg Pharma AB's overall GF Score™ is 60/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Moberg Pharma AB (FRA:MB8), the current PS Ratio is 27.66 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Moberg Pharma AB (FRA:MB8) Overvalued in 2026?
Based on GuruFocus' analysis, Moberg Pharma AB stock appears to be undervalued.
The current stock price of €0.80 is trading 24.3% below its estimated GF Value™ of €1.06.
Key valuation signals for FRA:MB8:
PS Ratio: 27.66 (650% above median its 10-year median of 3.69)
GF Value™: €1.06 vs. price of €0.80 (24.3% below fair value)
Industry Position: 1094.8% above the Drug Manufacturers median (#908 of 950)
No single metric tells the full story. See the FRA:MB8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.
60GF Score
Get the complete analysis for FRA:MB8
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MB8 has been successfully added to your 
